Marketing: Page 54
-
PhRMA distances itself from Marathon
The trade group broke its silence about the recent drug pricing controversy ignited by approval of PhRMA-member Marathon Pharmaceutical's DMD drug.
By Lisa LaMotta • Feb. 16, 2017 -
PBM scrutiny grows under pushback against rising costs
New York State is taking steps against pharmacy benefits managers, but the PBMs don't think they are to blame.
By Suzanne Elvidge • Feb. 15, 2017 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
Generics trade group rebrands, emphasizing 'accessible' medicines
GPhA's transformation into the Association for Accessible Medicines focuses on families and budgets, a sharp contrast to PhRMA's new Go Boldly marketing push.
By Judy Packer-Tursman • Feb. 15, 2017 -
Senators call on HHS' Price to fast track Canadian drug imports
Sens. Charles Grassley, Amy Klobuchar and John McCain are urging Trump's pick to consider an idea aimed at reducing the burden of high prescription drug costs.
By Jacob Bell • Feb. 14, 2017 -
Neurocrine enters licensing deal for Parkinson's drug
The company has agreed to pay Portuguese drugmaker Bial $30 million upfront for access to Ongentys, which gained approval in Europe last summer.
By Jacob Bell • Feb. 10, 2017 -
Courtesy of Regeneron Pharmaceuticals
Regeneron, Sanofi win reprieve from court ban on Praluent
But the biotech's forecast for slower sales of its key drug Eylea in 2017 will give investors a new concern to think over.
By Ned Pagliarulo • Feb. 9, 2017 -
FTC accuses Shire subsidiary of delaying generic rivals
According to a complaint filed Tuesday, Shire ViroPharma allegedly used "sham" citizen petitions to gum up FDA review of generic copies of its drug.
By Judy Packer-Tursman • Feb. 8, 2017 -
Express Scripts says branded drug prices rose nearly 11% last year
The large PBM contrasted those rising costs with the slower cost growth experienced by its members, touting its efforts to secure rebates from drugmakers.
By Jacob Bell • Feb. 6, 2017 -
Kaleo faces political pressure over drug price hikes
Democratic Senator Amy Klobuchar asked Kaleo for an explanation why it increased the price of its opioid overdose treatment by more than 500% over three years.
By Judy Packer-Tursman • Feb. 6, 2017 -
Novo Nordisk waffles due to US political uncertainty
The diabetes drugmaker is having trouble predicting future sales as a new administration in the U.S. begins setting policy goals for the industry.
By Lisa LaMotta • Feb. 2, 2017 -
Merck unveils new Keytruda DTC ad
With Bristol-Myers' Opdivo faltering, Merck is hammering home Keytruda's competitive advantage in first-line lung cancer.
By Jacob Bell • Feb. 1, 2017 -
Biogen nixes licensing deal for autoimmune drug
The Cambridge biotech had paid Mitsubishi Tanabe $60 million to gain access to the drug a year and a half ago, but hopes for a Gilenya competitor didn't pan out.
By Judy Packer-Tursman • Feb. 1, 2017 -
Pharma goes to Washington, Trump talks pricing
Pharmaceutical executives met with the new President and got the first sense of what the administration plans for the industry.
By Lisa LaMotta • Jan. 31, 2017 -
Biogen expects slow ramp for Spinraza
The big biotech was upbeat about prospects for Spinraza, but admitted there will be obstacles to a successful launch.
By Lisa LaMotta • Jan. 26, 2017 -
Payers balk at price of EpiPen rival
Kaleo Pharma set the list price of Auvi-Q at $4,500 — higher than Mylan's EpiPen — even as it promises low costs for patients.
By Jacob Bell • Jan. 25, 2017 -
PhRMA focuses on science, not pricing in new campaign
The industry lobbying group sidesteps hot button issues in its new ad campaign, focusing on biopharma's value and the "indomitable will' of its scientists.
By Judy Packer-Tursman • Jan. 25, 2017 -
FDA
FDA report stresses importance of Phase 3 testing
Several rumored candidates for FDA chief under President Trump have previously criticized the FDA approval process as being too slow.
By Judy Packer-Tursman • Jan. 25, 2017 -
Anthem limits coverage for Biogen's new SMA drug
Despite Spinraza's broad label, Anthem restricted coverage to only those patients with the most severe forms of the genetic disease.
By Ned Pagliarulo • Jan. 24, 2017 -
Shkreli bites back at industry ad campaign
Model of bad behavior or industry scapegoat?
By Lisa LaMotta • Jan. 24, 2017 -
J&J earnings disappoint, with no word on Actelion deal
In the wake of Donald Trump's recent criticisms of the industry, CEO Alex Gorsky sketched out new efforts to become more transparent on pricing.
By Ned Pagliarulo • Jan. 24, 2017 -
Deep Dive
7 companies to know in the emerging biosimilars field
Three more biosimilars won FDA approval last year and dozens more are moving through the pipeline. Here's some of the companies at the forefront of the growing drug class.
By Ned Pagliarulo • Jan. 23, 2017 -
5 hurdles facing biosimilar developers
While several biosimilars are poised to enter the U.S. market, there are still plenty of challenges that are affecting this new space of drugs.
By Lisa LaMotta • Jan. 23, 2017 -
FDA
Deep Dive
Biosimilars: What's in a name?
The FDA recently finalized naming conventions for biosimilars, putting in place an important piece of the regulatory framework for the copycat biologics.
By Ned Pagliarulo • Jan. 23, 2017 -
PhRMA-backed report analyzes 'complex process' of drug pricing
The report details how competition in the industry paired with strong PBM negotiating power can lead to price hikes, but not necessarily beefed-up profits for manufacturers.
By Jacob Bell • Jan. 19, 2017 -
FDA details thinking on off-label communications
The agency released two other draft guidance documents giving more clarity to the industry on medical product communications.
By Ned Pagliarulo • Jan. 19, 2017
Previous
